Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

STRKs sharp rally is drawing attention to Starknets post-quantum security narrative and discussion of a possible shift from an Ethereum L2 to an independent L1, alongside privacy and Bitcoin DeFi developments. Bullish traders point to the technology and momentum, while skeptics warn of profit-taking, token-unlock pressure, and a potential pump-and-dump reversal.

A reported Hyperbridge exploit involving an Ethereum-based wrapped DOT token is fueling security concerns, though some traders emphasize that native Polkadot DOT was not affected. The discussion also reflects sharp disagreement over DOTs weak price performance and whether recent rebounds can hold.

AEROs sharp move has traders focused on a test of the psychological $1 level, with bullish posts anticipating a breakout and others warning of resistance or a pullback. Optimism is also tied to the planned AerodromeVelodrome merger and broader multichain expansion, though the rollouts effect on the token remains uncertain.

NEONs volatile swings and persistent selling are driving discussion, with traders split between calling a bottom and expecting further declines. Some attribute the sharp moves to thin liquidity and raise concerns about token unlocks and circulating supply, while others see the selloff as a buying opportunity.

MoonLakes BLA submission for sonelokimab in hidradenitis suppurativa and the pending FDA review decision are driving discussion, with traders debating the potential for priority review against regulatory risk. The community is also weighing the muted share-price response and managements go-it-alone commercialization strategy against hopes for a partnership or buyout.

Visas strong quarterly results and resilient payment-volume growth are supporting a breakout to fresh highs, with traders also citing institutional buying and renewed bullish momentum. Some remain cautious about valuation, rising expenses and consumer-spending risks, while debate continues over stablecoins and other payment rails as longer-term competition.

Traders are focused on reports of FDA review documents showing a weaker response rate for daraxonrasib in KRAS G12D pancreatic cancer than in other mutation subgroups, raising questions about the drugs efficacy across patients and opening a competitive debate with Verastems G12D program. Some investors view the subgroup response data as concerning, while others argue that overall survival and progression-free-survival results matter more and caution that subgroup comparisons may not be definitive.

Adobes quarterly results beat expectations, but the stock reaction has been weighed down by concerns about its outlook, slowing recurring-revenue growth, and whether AI adoption will translate into paid growth. Traders remain divided between fears that AI tools could erode Adobes creative-software business and bullish views that its established products and cash generation remain resilient.

Bristol Myers is drawing attention over mixed pipeline developments: positive Phase 3 multiple-myeloma data and an expanded Camzyos indication are being weighed against a Leerink downgrade citing uncertainty around upcoming readouts and commercial prospects. Traders are debating whether the positive clinical progress can offset pipeline and execution concerns.

Rising Treasury yields and expectations for rates to stay higher for longer dominate discussion, with traders citing sticky inflation, possible Fed hikes, and Treasury supply concerns as pressure on IEF. The community is broadly bearish on bonds, though some see the selloff as overdone and view IEF as a buying opportunity if yields eventually ease.